Effects of long‐term treatment with the anti‐androgen bicalutamide on human testis: an ultrastructural and morphometric study

  title={Effects of long‐term treatment with the anti‐androgen bicalutamide on human testis: an ultrastructural and morphometric study},
  author={Emanuela Morgante and Roberto Gradini and Massimo Realacci and Patrizio Sale and G D'eramo and G A Perrone and Maria Rosaria Cardillo and Elisa Petrangeli and Matteo Antonio Russo and Franco di Silverio},
To assess the effects of more than 4 years' treatment with the anti‐androgen bicalutamide on human testis by clinical, ultrastructural and morphometric analysis. 

Impact of bicalutamide, an anti-androgen on rat testis

Treatment with bicalutamide induced various biochemical, histological and immunological changes in rat testis, and non-significant decrease in relative testis weight was caused.

Short-term antiandrogen flutamide treatment causes structural alterations in somatic cells associated with premature detachment of spermatids in the testis of pubertal and adult guinea pigs.

The transient exposition of the guinea pigs to flutamide, at all postnatal ages causes some degenerative lesions including severe premature detachment of spermatids and accumulation of myelin bodies in Leydig and Sertoli cells, compromising, at least temporarily, the sPermatogenesis.

Flutamide treatment reveals a relationship between steroidogenic activity of Leydig cells and ultrastructure of their mitochondria

It is demonstrated that increase in the expression level of steroidogenic proteins in rat testicular tissue as well as elevation of intratesticular sex steroid hormone levels observed in treated animals correspond well to morphological alterations of the Leydig cell ultrastructure.

FDA-approved drugs that are spermatotoxic in animals and the utility of animal testing for human risk prediction

The current animal models are not very effective for predicting human spermatotoxicity, and there is limited information available about the impact of many drugs on human spermatozoa.

Etude du ligand TRAIL et ses récepteurs dans la prostate normale et pathologique reliée au statut hormonal

Dans un modele de cancer prostatique humain hormonosensible greffe chez la souris nude traitee par un anti-androgene nous montrons l'expression des recepteurs au TRAIL, et de certains genes renseignant sur the relation entre croissance tumorale et statut hormonal.



Endocrine profiles during administration of the new non‐steroidal anti‐androgen Casodex in prostate cancer

OBJECTIVE Casodex (Zeneca) is a new potent, long‐acting non‐steroidal anti‐androgen, which produces androgen deprivation by blocking the androgen receptor. We evaluated the endocrine effects of

New hormonal therapy in prostatic carcinoma: combined treatment with an LHRH agonist and an antiandrogen.

It is indicated that a combined hormonal therapy which neutralizes all androgenic influences on peripheral tissues is of potential benefit in prostatic cancer and should minimize the development of metastases and androgen-resistant cell clones.

Clinical profile of a new non-steroidal antiandrogen

  • C. MahlerL. Denis
  • Medicine, Biology
    The Journal of Steroid Biochemistry and Molecular Biology
  • 1990

Comparison of LHRH analogue (Zoladex) with orchiectomy in patients with metastatic prostatic carcinoma.

A multicentre, randomised trial in the United Kingdom and the Republic of Ireland, in which the LHRH analogue Zoladex, administered subcutaneously every 28 days, was compared with orchiectomy found both treatments were equally effective in lowering serum testosterone concentrations to within the surgically castrate range.

Casodex: A pure non‐steroidal anti‐androgen used as monotherapy in advanced prostate cancer

The most commonly reported side‐effects were breast tenderness, breast swellings, breast swelling, and hot flashes, which are not associated with Casodex treatment.

Bicalutamide (Casodex®) in the treatment of prostate cancer: History of clinical development

Clinical trials are currently in progress to further evaluate bicalutamide as monotherapy in patients with advanced stages of disease and as adjuvant or first‐line therapy in patientswith early‐stage disease.

Update of hormonal treatment in cancer of the prostate.

Until recently orchiectomy and estrogens were the two main alternatives, but new compounds such as luteinizing hormone releasing hormone analogs and antiandrogens have shown to be as effective and less toxic than estrogens.

ICI 176,334: a novel non-steroidal, peripherally-selective antiandrogen.

  • B. Furr
  • Biology, Medicine
    Progress in clinical and biological research
  • 1988
A new non-steroidal antiandrogen ICI 176,334 (4'-cyano-3-(4-fluorophenylsulphonyl)-2-hydroxy-2-methyl-3'- trifluoromethyl)propion-anilide) has now been discovered which causes regression of the accessory sex organs but does not increase serum concentrations of LH and androgens.